What did Cowen change in the March 12, 2026 BTMD analyst rating update?

Cowen maintained a **Buy** on biote Corp. (BTMD) but lowered the price target to **$2.50** on March 12, 2026, signaling updated assumptions while preserving positive conviction.

How should investors interpret a maintained Buy with a lower price target in the BTMD analyst rating?

A maintained Buy with a reduced target typically means the analyst still sees net upside but adjusted inputs or higher risk; investors should reassess position size and valuation rather than treat it as a full downgrade.

How much did BTMD move after the Cowen note and how does coverage affect the stock?

The StreetInsider note shows a **-6.95% ($-0.11)** price move at the time of the update; limited analyst coverage can amplify moves, especially for a market cap of **$73,691,013**.

Where can I read the full analyst note and track BTMD analyst rating history?

See the StreetInsider summary of Cowen’s note for details and visit our Meyka BTMD page for ongoing coverage and analyst tracking to follow BTMD analyst rating changes.

Analyst Ratings

Cowen Maintains Buy on biote Corp. (BTMD) March 2026, PT $2.50

ByHuzaifa Zahoor March 13, 2026

Cowen & Co. maintained a Buy on biote Corp. (BTMD) on March 12, 2026, marking the latest BTMD analyst rating update. Cowen cut its price target to $2.50 while keeping the Buy stance, and the StreetInsider note shows a short-term price move of -6.95% ($-0.11) after the note. This change leaves Cowen as the sole active analyst in the recent feed, and it frames near-term expectations for investors weighing BTMD exposure.